JPM wrap: a BioCentury podcast

Takeouts, neuroscience innovation and investor sentiment to kick off 2024

Cautious optimism was the theme during a J.P. Morgan Healthcare Conference week that featured patchy skies, large-but-not-mega deals and a surfeit of sideline summits around San Francisco’s Union Square. BioCentury’s editorial team discusses the week’s M&A deals, including the $2 billion takeout of ADC company Ambrx Biopharma Inc. (NASDAQ:AMAM) by Johnson & Johnson (NYSE:JNJ), and Merck & Co. Inc. (NYSE:MRK) acquiring T cell engager biotech Harpoon Therapeutics Inc. (NASDAQ:HARP) for nearly $700 million; takeaways from the Sachs Neuroscience Innovation Forum and other adjacent forums; and investor sentiment heading into the New Year.